For ADC, DAC, bispecific/T-cell engager, and targeted degrader programs: quantify antigen density, receptor occupancy, target degradation, and mechanism-matched cytotoxicity directly in primary patient samples.
Designed for ADCs, DACs, bispecifics and T-cell engagers, and targeted degraders. Each assay is tailored to the relevant mechanism, including antigen expression, receptor occupancy or target engagement, payload or degradation activity, and effector-cell-mediated killing where applicable.
* Assay configuration is confirmed against your molecule during a no-cost feasibility review before scope is fixed.
Target-expression and antigen-density profiling
Flow-cytometric measurement of target expression in desired cell populations; quantitative antigen-density analysis where validated.
Target-engagement readouts
Receptor occupancy and target-protein degradation (e.g., for degrader programs), developed and qualified per target.
Immune-mediated cytotoxicity (on-request capability)
Cytotoxicity and killing-efficacy assays for bispecific and T-cell-engager candidates; assay design and feasibility confirmed at program scoping.
Population-resolved functional response
Response and engagement resolved within the malignant compartment — not averaged across the bulk well.
Target expression alone does not establish functional activity. xCellSense® connects target expression and engagement to functional response measured within defined malignant populations in primary patient-derived cells — helping development teams evaluate translational risk before clinical entry.
DEVELOPMENT DECISIONS SUPPORTED
A scientist — not a sales desk — will scope a tailored study and return a design and timeline.
